Progress in Huntington’s disease: the search for markers of disease onset and progression

Journal of Neurology

Volumn 262, Issue 8, 2015, Pages 1990-1995

  Mason, Sarah ^a   Barker, Roger A ^a,b  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

Cognition; Imaging; Lifestyle; Motor; Physiological; Psychiatric; Quality of life

Indexed keywords

ARTICLE; AUTONOMIC NERVOUS SYSTEM; COGNITIVE DEFECT; DISEASE COURSE; DISEASE MARKER; HUMAN; HUNTINGTON CHOREA; LIFESTYLE; PRIORITY JOURNAL; QUALITY OF LIFE; HUNTINGTON DISEASE;

BIOLOGICAL MARKER;

BIOMARKERS; DISEASE PROGRESSION; HUMANS; HUNTINGTON DISEASE;

EID: 84939265716     PISSN: 03405354     EISSN: 14321459     Source Type: Journal    
DOI: 10.1007/s00415-015-7700-0     Document Type: Article

References (44)

1. Andrich J, Schmitz T, Saft C, Postert T, Kraus P, Epplen JT, Przuntek H, Agelink MW (2002) Autonomic nervous system function in Huntington’s disease. J Neurol Neurosurg Psychiatry 72:726–731
2. Aylward EH, Anderson NB, Bylsma FW, Wagster MV, Barta PE, Sherr M, Feeney J, Davis A, Rosenblatt A, Pearlson GD, Ross CA (1998) Frontal lobe volume in patients with Huntington’s disease. Neurology 50:252–258
3. Aylward EH, Codori AM, Barta PE, Pearlson GD, Harris GJ, Brandt J (1996) Basal ganglia volume and proximity to onset in presymptomatic Huntington disease. Arch Neurol 53:1293–1296
4. Aziz NA, Anguelova GV, Marinus J, van Dijk JG, Roos RA (2010) Autonomic symptoms in patients and pre-manifest mutation carriers of Huntington’s disease. Eur J Neurol 17:1068–1074
5. Begeti F, Tan AY, Cummins GA, Collins LM, Guzman NV, Mason SL, Barker RA (2013) The Addenbrooke’s Cognitive Examination-Revised accurately detects cognitive decline in Huntington’s disease. J Neurol 260:2777–2785
6. Byars JA, Beglinger LJ, Moser DJ, Gonzalez-Alegre P, Nopoulos P (2012) Substance abuse may be a risk factor for earlier onset of Huntington disease. J Neurol 259:1824–1831
7. Csernansky JG, Dong H, Fagan AM, Wang L, Xiong C, Holtzman DM, Morris JC (2006) Plasma cortisol and progression of dementia in subjects with Alzheimer-type dementia. Am J Psychiatry 163:2164–2169
8. Dumas EM, van den Bogaard SJ, Middelkoop HA, Roos RA (2013) A review of cognition in Huntington’s disease. Front Biosci (Schol Ed) 5:1–18
9. Dumas EM, van den Bogaard SJ, Ruber ME, Reilman RR, Stout JC, Craufurd D, Hicks SL, Kennard C, Tabrizi SJ, van Buchem MA, van der Grond J, Roos RA (2012) Early changes in white matter pathways of the sensorimotor cortex in premanifest Huntington’s disease. Hum Brain Mapp 33:203–212
10. Dumas JA, Kutz AM, McDonald BC, Naylor MR, Pfaff AC, Saykin AJ, Newhouse PA (2013) Increased working memory-related brain activity in middle-aged women with cognitive complaints. Neurobiol Aging 34:1145–1147
11. Goodman AO, Rogers L, Pilsworth S, McAllister CJ, Shneerson JM, Morton AJ, Barker RA (2011) Asymptomatic sleep abnormalities are a common early feature in patients with Huntington’s disease. Curr Neurol Neurosci Rep 11:211–217
12. Harris GJ, Codori AM, Lewis RF, Schmidt E, Bedi A, Brandt J (1999) Reduced basal ganglia blood flow and volume in pre-symptomatic, gene-tested persons at-risk for Huntington’s disease. Brain 122(Pt 9):1667–1678
13. Hart EP, Dumas EM, Reijntjes RH, van der Hiele K, van den Bogaard SJ, Middelkoop HA, Roos RA, van Dijk JG (2012) Deficient sustained attention to response task and P300 characteristics in early Huntington’s disease. J Neurol 259:1191–1198
14. Hart EP, Dumas EM, van Zwet EW, van der Hiele K, Jurgens CK, Middelkoop HA, van Dijk JG, Roos RA (2013). Longitudinal pilot-study of Sustained attention to response task and P300 in manifest and pre-manifest Huntington’s disease. J Neuropsychol
15. Herben-Dekker M, van Oostrom JC, Roos RA, Jurgens CK, Witjes-Ane MN, Kremer HP, Leenders KL, Spikman JM (2014) Striatal metabolism and psychomotor speed as predictors of motor onset in Huntington’s disease. J Neurol 261:1387–1397
16. Hocaoglu MB, Gaffan EA, Ho AK (2012) Health-related quality of life in Huntington’s disease patients: a comparison of proxy assessment and patient self-rating using the disease-specific Huntington’s disease health-related quality of life questionnaire (HDQoL). J Neurol 259:1793–1800
17. Johnson JM, Kellogg DL Jr (2010) Local thermal control of the human cutaneous circulation. J Appl Physiol 109:1229–1238
18. Kobal J, Melik Z, Cankar K, Bajrovic FF, Meglic B, Peterlin B, Zaletel M (2010) Autonomic dysfunction in presymptomatic and early symptomatic Huntington’s disease. Acta Neurol Scand 121:392–399
19. Kobal J, Melik Z, Cankar K, Strucl M (2014) Cognitive and autonomic dysfunction in presymptomatic and early Huntington’s disease. J Neurol
20. Lawrence AD, Hodges JR, Rosser AE, Kershaw A, Ffrench-Constant C, Rubinsztein DC, Robbins TW, Sahakian BJ (1998) Evidence for specific cognitive deficits in preclinical Huntington’s disease. Brain 121(Pt 7):1329–1341
21. Lawrence AD, Sahakian BJ, Rogers RD, Hodge JR, Robbins TW (1999) Discrimination, reversal, and shift learning in Huntington’s disease: mechanisms of impaired response selection. Neuropsychologia 37:1359–1374
22. Lopez-Sendon JL, Royuela A, Trigo P, Orth M, Lange H, Reilmann R, Keylock J, Rickards H, Piacentini S, Squitieri F, Landwehrmeyer B, Witjes-Ane MN, Jurgens CK, Roos RA, Abraira V, de Yebenes JG, European HDN (2011) What is the impact of education on Huntington’s disease? Mov Disord 26:1489–1495
23. Melik Z, Kobal J, Cankar K, Strucl M (2012) Microcirculation response to local cooling in patients with Huntington’s disease. J Neurol 259:921–928
24. Minson CT (2010) Thermal provocation to evaluate microvascular reactivity in human skin. J Appl Physiol 109:1239–1246
25. Orth M, Handley OJ, Schwenke C, Dunnett SB, Craufurd D, Ho AK, Wild E, Tabrizi SJ, Landwehrmeyer GB, Investigators of the European huntington’s disease N (2010) Observing Huntington’s disease: the European Huntington’s disease network’s registry. PLoS Curr 2:RRN1184
26. Papp KV, Snyder PJ, Mills JA, Duff K, Westervelt HJ, Long JD, Lourens S, Paulsen JS (2013) Measuring executive dysfunction longitudinally and in relation to genetic burden, brain volumetrics, and depression in prodromal Huntington disease. Arch Clin Neuropsychol 28:156–168
27. Paulsen JS, Langbehn DR, Stout JC, Aylward E, Ross CA, Nance M, Guttman M, Johnson S, Macdonald M, Beglinger LJ, Duff K, Kayson E, Biglan K, Shoulson I, Oakes D, Hayden M (2008) Detection of Huntington’s disease decades before diagnosis: the Predict-HD study. J Neurol Neurosurg Psychiatry 79:874–880
28. Paulsen JS, Magnotta VA, Mikos AE, Paulson HL, Penziner E, Andreasen NC, Nopoulos PC (2006) Brain structure in preclinical Huntington’s disease. Biol Psychiatry 59:57–63
29. Petersen A, Bjorkqvist M (2006) Hypothalamic-endocrine aspects in Huntington’s disease. Eur J Neurosci 24:961–967
30. Pirogovsky E, Goldstein J, Peavy G, Jacobson MW, Corey-Bloom J, Gilbert PE (2009) Temporal order memory deficits prior to clinical diagnosis in Huntington’s disease. J Int Neuropsychol Soc 15:662–670
31. Rosas HD, Tuch DS, Hevelone ND, Zaleta AK, Vangel M, Hersch SM, Salat DH (2006) Diffusion tensor imaging in presymptomatic and early Huntington’s disease: selective white matter pathology and its relationship to clinical measures. Mov Disord 21:1317–1325
32. Sapolsky RM (2000) Glucocorticoids and hippocampal atrophy in neuropsychiatric disorders. Arch Gen Psychiatry 57:925–935
33. Scoville WB, Milner B (1957) Loss of recent memory after bilateral hippocampal lesions. J Neurol Neurosurg Psychiatry 20:11–21
34. Shirbin CA, Chua P, Churchyard A, Hannan AJ, Lowndes G, Stout, JC (2012) The relationship between cortisol and verbal memory in the early stages of Huntington’s disease. J Neurol
35. Simonin C, Duru C, Salleron J, Hincker P, Charles P, Delval A, Youssov K, Burnouf S, Azulay JP, Verny C, Scherer C, Tranchant C, Goizet C, Debruxelles S, Defebvre L, Sablonniere B, Romon-Rousseaux M, Buee L, Destee A, Godefroy O, Durr A, Landwehrmeyer B, Network RSOTEHSD, Bachoud-Levi AC, Richard F, Blum D, Krystkowiak P, Huntington French Speaking N (2013) Association between caffeine intake and age at onset in Huntington’s disease. Neurobiol Dis 58:179–182
36. Solomon AC, Stout JC, Johnson SA, Langbehn DR, Aylward EH, Brandt J, Ross CA, Beglinger L, Hayden MR, Kieburtz K, Kayson E, Julian-Baros E, Duff K, Guttman M, Nance M, Oakes D, Shoulson I, Penziner E, Paulsen JS (2007) Verbal episodic memory declines prior to diagnosis in Huntington’s disease. Neuropsychologia 45:1767–1776
37. Stout JC, Paulsen JS, Queller S, Solomon AC, Whitlock KB, Campbell JC, Carlozzi N, Duff K, Beglinger LJ, Langbehn DR, Johnson SA, Biglan KM, Aylward EH (2011) Neurocognitive signs in prodromal Huntington disease. Neuropsychology 25:1–14
38. Tabrizi SJ, Reilmann R, Roos RA, Durr A, Leavitt B, Owen G, Jones R, Johnson H, Craufurd D, Hicks SL, Kennard C, Landwehrmeyer B, Stout JC, Borowsky B, Scahill RI, Frost C, Langbehn DR, Investigators T-H (2012) Potential endpoints for clinical trials in premanifest and early Huntington’s disease in the TRACK-HD study: analysis of 24 month observational data. Lancet Neurol 11:42–53
39. Tabrizi SJ, Scahill RI, Durr A, Roos RA, Leavitt BR, Jones R, Landwehrmeyer GB, Fox NC, Johnson H, Hicks SL, Kennard C, Craufurd D, Frost C, Langbehn DR, Reilmann R, Stout JC, Investigators T-H (2011) Biological and clinical changes in premanifest and early stage Huntington’s disease in the TRACK-HD study: the 12-month longitudinal analysis. Lancet Neurol 10:31–42
40. Tabrizi SJ, Scahill RI, Owen G, Durr A, Leavitt BR, Roos RA, Borowsky B, Landwehrmeyer B, Frost C, Johnson H, Craufurd D, Reilmann R, Stout JC, Langbehn DR (2013) Predictors of phenotypic progression and disease onset in premanifest and early-stage Huntington’s disease in the TRACK-HD study: analysis of 36-month observational data. Lancet Neurol 12:637–649
41. Tabrizi SJ, Scahill RI, Owen G, Durr A, Leavitt BR, Roos RA, Borowsky B, Landwehrmeyer B, Frost C, Johnson H, Craufurd D, Reilmann R, Stout JC, Langbehn DR, Investigators T-H (2013) Predictors of phenotypic progression and disease onset in premanifest and early-stage Huntington’s disease in the TRACK-HD study: analysis of 36-month observational data. Lancet Neurol 12:637–649
42. Thieben MJ, Duggins AJ, Good CD, Gomes L, Mahant N, Richards F, McCusker E, Frackowiak RS (2002) The distribution of structural neuropathology in pre-clinical Huntington’s disease. Brain 125:1815–1828
43. van den Bogaard SJ, Dumas EM, Acharya TP, Johnson H, Langbehn DR, Scahill RI, Tabrizi SJ, van Buchem MA, van der Grond J, Roos RA (2011) Early atrophy of pallidum and accumbens nucleus in Huntington’s disease. J Neurol 258:412–420
44. Watkins LH, Rogers RD, Lawrence AD, Sahakian BJ, Rosser AE, Robbins TW (2000) Impaired planning but intact decision making in early Huntington’s disease: implications for specific fronto-striatal pathology. Neuropsychologia 38:1112–1125